• Blog
  • Immunology Drug Market Report Analysis

    Immunology Drug Market Report Analysis

    Immunology Drug Market Report Analysis
    Report code - SR1480 Delivery - 2 Weeks
    Get Free Sample |
    Immunology Drug Market Size, Share, Growth, Forecast, & Industry Analysis
    See more...

    Market Insights

    The Immunology Drug market was estimated to grow from USD 92.89 billion in 2021 to USD 160.91 billion by 2028 at a CAGR of around 8.13% during the forecast period.

    Immunology Drug Market Size

    Wish to get a free sample? Register Here

    What is immune system?

    The immune system is a combination of structures and processes inside the body to protect against possibly damaging foreign bodies and diseases. It identifies several threats such as viruses, bacteria, and parasites and distinguishes them from the body's healthy tissues. These drugs aid in curing autoimmune diseases. The drugs also help in killing cancer cells and have become the preferred choice of many.

    Key Players

    Key players operating in the immunology drug market are-

    • Pfizer Inc. (U.S.)
    • F. Hoffmann-La Roche Ltd. (Switzerland)
    • AbbVie, Inc. (U.S.)
    • Bristol-Myers Squibb Company (U.S.)
    • Merck Sharp & Dohme Corp. (U.S.)
    • Novartis AG (Switzerland)
    • Janssen Global Services, LLC (U.S.)
    • Amgen Inc. (U.S.)
    • Astellas Pharma Inc. (Japan)
    • UCB SA (Belgium)

    Market Dynamics

    The rise in the prevalence rate of various types of cancer and rheumatoid cancer, growing funding from the various government & non-government organizations, and increasing government initiatives, are some of the key factors augmenting the immunology drug market growth. Moreover, patients with poor prognoses are further expected to boost the growth of the immunology drug trial evidence reveals which after preparing the immune system to fight against cancer immunology, drug effects last for a long time even after the reduction of the tumor. However, the high cost of these drugs is likely to hamper industry growth.

    Get the full scope of the report. Register Here

    Segment Analysis

    By Drug Type

    The immunology drug market has been classified into monoclonal antibodies (mAb), antibody-drug conjugates, interferon and cytokine therapies, immunosuppressive medication. Under these, the monoclonal antibodies (mAb) segment accounted for a significant market share in 2021 and is projected to register significant growth during the review period. This is mainly attributed to the rising number of approvals for mAb by the government bodies to treat chronic ailments across the globe, further fostering segment growth.

    By Region

    The market in North America accounted for a significant market share in 2021 and is projected to grow at a significant CAGR during the assessment period. This is mainly ascribed to the rising prevalence of chronic ailments, robust healthcare infrastructure, the higher diagnosis rate of the patients, increasing healthcare expenditure, and a large number of home healthcare facilities, which further proliferates the regional market growth.

    Know which region offers the best growth opportunities. Register Here

     

    Market Segmentation

    This report studies the market covering a period of 12 years of trend and forecast. The report provides detailed insights into the market dynamics to enable informed business decision-making and growth strategy formulation based on the opportunities present in the market.

    Report – Features

    Market Segmentation

    3

    Regions Covered

    4

    Countries/Sub-Regions Covered

    14

    No. of Figures & Tables

    >150

    Company Profiles

    10

     

    The market is segmented into the following categories. 

    By Drug Type

    • Monoclonal Antibodies (mAb)
    • Antibody Drug Conjugates
    • Interferon and Cytokine therapies
    • Immunosuppressive medication

    By Application Type 

    • Hospitals
    • Clinics
    • Cancer Research Centers and Institutes

    By Region

    • North America
    • Asia-Pacific
    • Europe
    • Rest of the World

    Want to get more details about the segmentations, Click here

     

    COVID-19 Impact

    The COVID-19 outbreak positively influenced the immunology drug market growth. The growing use of immunology drugs in the treatment of COVID-19 infection can be effective in the management of the disease. The pandemic has increased the demand for immunology drugs as people are consuming these products to prevent the transmission of coronavirus across the globe. Hence, several manufacturers are trying to develop new products to keep up with the high demand, thus boosting the market growth.

    Critical Questions Answered in the Report

    • What are the key trends in the market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the market?
    • What are the key strategies adopted by the major vendors to lead in the market?
    • What is the market share of the top vendors?

    Target Audience

    Here is the list of the group of customers that the market hopes to have the greatest opportunity to convert-

    • Distributors
    • Suppliers
    • Manufacturers
    • Logistics organizations
    • Government bodies

    Report Features

    This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market. The following are the key features of the report:

    • Overview, industry life cycle analysis, supply chain analysis.
    • Environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis.
    • Trend and forecast analysis.
    • Segment trend and forecast.
    • Competitive landscape and dynamics: Market share, Product portfolio, New Product Launches, etc.
    • Attractive market segments and associated growth opportunities.
    • Emerging trends.
    • Strategic growth opportunities for the existing and new players.
    • Key success factors.

    Immunology Drug Market Features

    Market Size in 2028

    USD 160.91 billion

    Market Size in 2021

    USD 92.89 billion

    Market Growth (2022-2028)

    8.13 CAGR

    Base Year of Study

    2021

    Trend Period

    2016-2020

    Forecast Period

    2022-2028

    Segments Covered

    By Drug Type (Monoclonal Antibodies (mAb), Antibody Drug Conjugates, Interferon and Cytokine therapies, Immunosuppressive medication),

    By Application (Hospitals, Clinics, Cancer Research Centers and Institutes),

    By Region (North America, APAC, Europe, Rest of the World).

    Top Companies in 2022

    • Pfizer Inc. (U.S.)
    • F. Hoffmann-La Roche Ltd. (Switzerland)
    • AbbVie, Inc. (U.S.)
    • Bristol-Myers Squibb Company (U.S.)
    • Merck Sharp & Dohme Corp. (U.S.)
    • Novartis AG (Switzerland)
    • Janssen Global Services, LLC (U.S.)
    • Amgen Inc. (U.S.)
    • Astellas Pharma Inc. (Japan)
    • UCB SA (Belgium)

    Dominant Region

    The North American market accounted for the largest market share in 2021.

    Research Methodology

    This strategic assessment report, from Stratview Research, provides a comprehensive analysis that reflects today’s market realities and future market possibilities for the forecast period of 2022 to 2028.

    The report segments and analyzes the market in the most detailed manner in order to provide a panoramic view of the market.

    The vital data/information provided in the report can play a crucial role for the market participants as well as investors in the identification of the low-hanging fruits available in the market as well as to formulate the growth strategies to expedite their growth process.

    This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. 

    More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. 

    We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

    Report Customization

    With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

    Company Profiling

    • Detailed profiling of additional market players (up to three players)
    • SWOT analysis of key players (up to three players)

    Competitive Benchmarking

    Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    The immune system is a combination of structures and processes inside the body to protect against possibly damaging foreign bodies and diseases. It identifies several threats such as viruses, bacteria, and parasites and distinguishes them from the body's healthy tissues. These drugs aid in curing autoimmune diseases. The drugs also help in killing cancer cells and have become the preferred choice of many.

    The immunology drug market is projected to grow from USD 92.89 billion in 2021 to USD 160.91 billion by 2028.

    The immunology drug market is expected to witness an impressive growth of 8.13% CAGR in the coming years.

    Pfizer Inc. (U.S.) F. Hoffmann-La Roche Ltd. (Switzerland) AbbVie, Inc. (U.S.) Bristol-Myers Squibb Company (U.S.) Merck Sharp & Dohme Corp. (U.S.) Novartis AG (Switzerland) Janssen Global Services, LLC (U.S.) Amgen Inc. (U.S.) Astellas Pharma Inc. (Japan) UCB SA (Belgium)

    North America accounted for the largest share in the immunology drug market in 2021.

    The rise in the prevalence rate of various types of cancer and rheumatoid cancer, growing funding from the various government & non-government organizations, and increasing government initiatives, are some of the key factors augmenting the immunology drug market growth. Moreover, patients with poor prognoses are further expected to boost the growth of the immunology drug trial evidence reveals which after preparing the immune system to fight against cancer immunology, drug effects last for a long time even after the reduction of the tumor. However, the high cost of these drugs is likely to hamper industry growth.

    The monoclonal antibodies (mAb) segment accounted for a significant market share in 2021.

    By Drug Type (Monoclonal Antibodies (mAb), Antibody Drug Conjugates, Interferon and Cytokine therapies, Immunosuppressive medication), By Application (Hospitals, Clinics, Cancer Research Centers and Institutes), and Region (North America, APAC, Europe, Rest of the World).

    •   
    ×